Answers are grounded in this paper and cite their sources.
From Inotek Pharmaceuticals Corporation, Beverly, MA, and the Department of Human Physiology and Clinical Experimental Research, Semmelweis University Medical School, Budapest, Hungary. Between 1999 and 2003, work in the laboratory of the author in the area of nitrosative stress and cell necrosis was funded by an R01 grant from the National Institutes of Health. The author is employed by Inotek Pharma, has equity interest, and owns stock in the company. He also holds a patent with Inotek Pharma.
No takes yet. Share an insight, caveat, or question.
Csaba Szabó (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: